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cessfully developing condition-speciﬁc formularies. Annually an
estimated $456.00 and $1813.00 drug cost savings could be
achieved by the hospice as a result of implementing depression
and CHF formularies.
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OBJECTIVES: Growing interest in the use of Drug Eluting Stents
(DES) in coronary angioplasty has prompted the Health Care
Agency of the Emilia Romagna Region to draw up recommen-
dations for their appropriate clinical use. Since the adoption of
any new technology necessitates economic appraisal, we have
analyzed the resource consumption by type of angioplasty pro-
cedure as well as the impact on the budget of a cardiology
department. METHODS: A retrospective economic evaluation
has been carried out on the angioplasty procedures performed in
2004 in the Cardiology Department of Reggio Emilia hospital.
Using the Activity Based Costing method, detailed hospital costs
have been estimated for each procedure and compared with the
pertinent Italian DRG fees. RESULTS: In 2004, the Interven-
tional Cardiology Department of Santa Maria Nuova Hospital
in Reggio Emilia performed 806 angioplasty procedures for a
total expenditure of €5,176,268. These were: 93 Plain Old
Balloon Angioplasties (POBA) (€487,329), 401 procedures using
Bare Metal Stents (BMS) (€2,380,071), 249 procedures using
Drug Eluting Stents (DES) (€1,827,386) and 63 MIXED proce-
dures (€481,480). Reimbursement via DRG funding amounted
for €5,816,748 (11% for POBA, 50% for BMS, 31% for DES
and 8% for MIXED procedures). The overall case-mix of the
performed angioplasty procedures generated a positive margin
of about €680,480 between the costs incurred and the reim-
bursement obtained. CONCLUSIONS: Analysis of the case-mix
of procedures revealed that, although the adoption of innovative
technologies increases costs, an overall positive margin between
costs and DRG reimbursements can be achieved. It therefore
emerges that, adherence in clinical practice to the guidelines
designed by the Health Care Agency of the Emilia Romagna
Region is economically sustainable from the point of view of the
hospital-enterprise.
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OBJECTIVES: To review reported economic evaluations of
myocardial perfusion scintigraphy (MPS) for patients with sus-
pected coronary artery disease (CAD); to synthesise and com-
municate two reviews undertaken to support an appraisal of
MPS in this technology by the UK National Institute for Health
and Clinical Excellence (NICE). METHODS: Conduct a sys-
tematic review to identify published studies reporting economic
evaluations comparing diagnostic strategies with and without
MPS in patients with chest pain and/or abnormal resting ECG.
Studies published between 1984 and 2002 were included,
together with two model-based evaluations submitted to NICE
in 2003. Results were summarised by source of data, strategy
comparison and type of patient. Quality of reported studies and
methodological issues were assessed. RESULTS: Twenty-four
studies were identiﬁed: 12 ‘primary’ studies based on analyses of
prospective or retrospective data and 12 studies based on deci-
sion-analytic modelling. Twenty studies were based in the US and
4 in the UK, one of which used data from a range of European
countries. Many studies reported that MPS was a cost-effective
alternative to Exercise ECG (ExECG) prior to coronary angiog-
raphy (CA) in patients at intermediate/high risk of CAD. Evi-
dence for the cost-effectiveness of adding MPS after ExECG (in
patient’s positive on ExECG) was less conclusive. Compared
with MPS, direct CA was generally not cost-effective in patients
at intermediate risk, but cost-saving for patients at high risk.
Studies were of variable quality; for example primary studies
based on short term outcomes, and failure to present incremen-
tal comparisons. The use of CA as a gold standard for functional
imaging tests which provide additional information to the degree
of vessel stenosis may be problematic. CONCLUSION: There 
is evidence for the cost-effectiveness of MPS in patients at 
intermediate risk of CAD. It would be valuable to conﬁrm this
with longer term prospective studies and improved economic
modelling.
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OBJECTIVES: To estimate the drug acquisition cost savings for
third payer payers (TPPs) with the availability of generic sim-
vastatin in the United States. METHODS: A deterministic study
ascertained the potential cost savings for TPPs in the year fol-
lowing generic simvastatin availability. The study focused on
patients requiring cholesterol reduction (>30% LDL-C reduc-
tion). Annual national statin prescription sales (November
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